论文部分内容阅读
衣霉素(Tunicamycin)是一种糖蛋白N-连接型糖链合成的抑制剂。它可抑制人肝癌细胞抹SMMC-7721的生长,其抑制率和剂量及处理时间有相关性。衣霉素处理细胞18h尚可显著抑制~3H-甘露糖和~3H-氨基葡萄糖参入细胞,但仅轻度抑制~3H-亮氨酸的参入。这些标记化合物的参入抑制都有量效关系。0.1gg/mL衣霉素处理18h后,细胞表面胰岛素受体和胰岛素的结合容量下降,而对照细胞和处理细胞的胰岛素竞争结合曲线基本平行。这主要由于衣霉素抑制新合成的胰岛素受体的糖基化所致。我们对糖基化障碍引起细胞膜胰岛素受体结合容量降低的机理作了讨论。
Tunicamycin is a glycoprotein inhibitor of N-linked sugar chain synthesis. It can inhibit the growth of human hepatoma SMMC-7721 cells, the inhibition rate and dose and treatment time are related. Tunicamycin treatment of cells 18h significantly inhibited ~ 3H-mannose and ~ 3H-glucosamine into the cells, but only slightly inhibited the 3H-leucine incorporation. The inhibition of the incorporation of these labeled compounds has a dose-effect relationship. After treatment with 0.1gg / ml tunicamycin for 18h, the binding capacity of insulin receptor to insulin on the cell surface decreased, while that of control cells and treated cells was almost parallel. This is primarily due to tunicamycin inhibiting glycosylation of the newly synthesized insulin receptor. We discuss the mechanism by which glycosylation disrupts the binding capacity of the plasma membrane insulin receptor.